A New Dawn for Depression Treatment
At the heart of Draig’s mission is a relentless focus on hard-to-drug targets in neuropsychiatric conditions — a therapeutic frontier that has long stymied drugmakers. Its lead asset, DT-101, is now poised to enter phase II clinical trials, funded by the new injection of capital.
“We were drawn to Draig’s bold scientific vision,” said Charles Dunn, principal at SV Health Investors. “The founding team has shown exceptional promise in cracking the code of previously elusive neurological targets.”
Draig’s CEO emphasized that the funding would propel rigorous clinical trials, team expansion, and further development of its proprietary drug discovery platform, aimed at major depressive disorder and other mental health conditions.
Leadership and Strategic Growth
ICG, which has been deeply involved in the company’s trajectory, announced that Samantha Budd Haeberlein — former Chief Medical Officer and now senior adviser to its life sciences division — will join Draig’s board of directors. Her leadership is expected to lend seasoned oversight as the company scales.
“Draig has a great platform from which to make a meaningful impact on neuropsychiatric care,” said Haeberlein. “This financing round is just the beginning of what’s possible.”
